Senate drug transparency bill stripped of key tracking provisions before full vote

The short version

• Senate lawmakers modified the Clear Labels Act by removing a requirement for unique FDA facility identification numbers on generic drug labels, according to ProPublica.[ProPublica]
• The revised legislation extends the compliance timeline for pharmaceutical companies to five years before full implementation.[ProPublica]
• People familiar with the process stated that lawmakers feared precise location disclosures could raise drug prices and impact national security.[ProPublica]
• The updated bill cleared the Senate Committee on Health, Education, Labor and Pensions in July with a single dissenting vote.[ProPublica]

Key facts

• Sens. Rick Scott and Kirsten Gillibrand originally introduced the Clear Labels Act to increase pharmaceutical supply chain transparency.[ProPublica]
• Lawmakers removed a requirement for unique FDA facility identification numbers from the bill and set a five-year compliance window.[ProPublica]
• The revised legislation passed the Senate Committee on Health, Education, Labor and Pensions in July with Sen. Rand Paul as the sole dissenting vote.[ProPublica]
• The Association for Accessible Medicines spent over $1 million between January and July lobbying on healthcare bills, including the Clear Labels Act.[ProPublica]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.

• “A Clear Watering Down”: Drug Transparency Bill Stripped of Critical Provisions Ahead of Senate VoteProPublica